Merck & Company Inc (MRK)vsNovo Nordisk A/S (NVO)
MRK
Merck & Company Inc
$133.72
+0.69%
HEALTHCARE · Cap: $362.27B
NVO
Novo Nordisk A/S
$37.82
-2.70%
HEALTHCARE · Cap: $177.74B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 395% more annual revenue ($333.65B vs $67.38B). NVO leads profitability with a 33.9% profit margin vs 3.6%. MRK appears more attractively valued with a PEG of 3.56. NVO earns a higher WallStSmart Score of 59/100 (C).
MRK
Hold42
out of 100
Grade: D
NVO
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-56.0%
Fair Value
$85.13
Current Price
$133.72
$48.59 premium
Intrinsic value data unavailable for NVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 35.2%
Generating 5.5B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 52 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 40.1%
Generating 28.1B in free cash flow
Large-cap with strong market position
Areas to Watch
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Earnings declined 15.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.9% and operating margin at 40.1%.
Bear Case : MRK
The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
MRK profiles as a value stock while NVO is a mature play — different risk/reward profiles.
NVO carries more volatility with a beta of 0.37 — expect wider price swings.
NVO is growing revenue faster at 5.6% — sustainability is the question.
NVO generates stronger free cash flow (28.1B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (59/100 vs 42/100), backed by strong 33.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?